183 related articles for article (PubMed ID: 28916818)
1. Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt.
Huang BX; Newcomer K; Kevala K; Barnaeva E; Zheng W; Hu X; Patnaik S; Southall N; Marugan J; Ferrer M; Kim HY
Sci Rep; 2017 Sep; 7(1):11673. PubMed ID: 28916818
[TBL] [Abstract][Full Text] [Related]
2. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
[TBL] [Abstract][Full Text] [Related]
3. Modulator of the PI3K/Akt oncogenic pathway affects mTOR complex 2 in human adenocarcinoma cells.
Curless BP; Uko NE; Matesic DF
Invest New Drugs; 2019 Oct; 37(5):902-911. PubMed ID: 30542835
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1.
Hiromura M; Okada F; Obata T; Auguin D; Shibata T; Roumestand C; Noguchi M
J Biol Chem; 2004 Dec; 279(51):53407-18. PubMed ID: 15459205
[TBL] [Abstract][Full Text] [Related]
5. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
Sommer EM; Dry H; Cross D; Guichard S; Davies BR; Alessi DR
Biochem J; 2013 Jun; 452(3):499-508. PubMed ID: 23581296
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
7. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
[TBL] [Abstract][Full Text] [Related]
8. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Zhang X; Zhong S
Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
[TBL] [Abstract][Full Text] [Related]
9. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
Falasca M; Chiozzotto D; Godage HY; Mazzoletti M; Riley AM; Previdi S; Potter BV; Broggini M; Maffucci T
Br J Cancer; 2010 Jan; 102(1):104-14. PubMed ID: 20051961
[TBL] [Abstract][Full Text] [Related]
10. Pleckstrin homology domain of Akt kinase: a proof of principle for highly specific and effective non-enzymatic anti-cancer target.
Joh EH; Hollenbaugh JA; Kim B; Kim DH
PLoS One; 2012; 7(11):e50424. PubMed ID: 23189201
[TBL] [Abstract][Full Text] [Related]
11. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
[TBL] [Abstract][Full Text] [Related]
12. 3-Arylamino-quinoxaline-2-carboxamides inhibit the PI3K/Akt/mTOR signaling pathways to activate P53 and induce apoptosis.
Chen NY; Lu K; Yuan JM; Li XJ; Gu ZY; Pan CX; Mo DL; Su GF
Bioorg Chem; 2021 Sep; 114():105101. PubMed ID: 34175723
[TBL] [Abstract][Full Text] [Related]
13. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
14. Calpain-2 activates Akt via TGF-β1-mTORC2 pathway in pulmonary artery smooth muscle cells.
Abeyrathna P; Kovacs L; Han W; Su Y
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C24-34. PubMed ID: 27099352
[TBL] [Abstract][Full Text] [Related]
15. FRET biosensor-based kinase inhibitor screen for ERK and AKT activity reveals differential kinase dependencies for proliferation in TNBC cells.
He J; Wink S; de Bont H; Le Dévédec S; Zhang Y; van de Water B
Biochem Pharmacol; 2019 Nov; 169():113640. PubMed ID: 31536726
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.
Barnett SF; Defeo-Jones D; Fu S; Hancock PJ; Haskell KM; Jones RE; Kahana JA; Kral AM; Leander K; Lee LL; Malinowski J; McAvoy EM; Nahas DD; Robinson RG; Huber HE
Biochem J; 2005 Jan; 385(Pt 2):399-408. PubMed ID: 15456405
[TBL] [Abstract][Full Text] [Related]
17. AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells.
Rabi T; Huwiler A; Zangemeister-Wittke U
Mol Carcinog; 2014 Jul; 53(7):578-88. PubMed ID: 23475563
[TBL] [Abstract][Full Text] [Related]
18. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
19. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
20. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
Sathe A; Chalaud G; Oppolzer I; Wong KY; von Busch M; Schmid SC; Tong Z; Retz M; Gschwend JE; Schulz WA; Nawroth R
PLoS One; 2018; 13(1):e0190854. PubMed ID: 29357370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
